테스토스테론 보충 요법 시장 : 제품 유형별, 유효 성분별, 최종사용자별 - 세계 기회 분석과 산업 예측(2023-2032년)

The global testosterone replacement therapy market was valued at $1.9 billion in 2022, and is projected to reach $2.9 billion by 2032, growing at a CAGR of 4.2% from 2023 to 2032.

Testosterone replacement therapy is a medical intervention designed to address low levels of testosterone. Testosterone is a crucial hormone responsible for the development of male reproductive tissues and the maintenance of male characteristics, such as muscle mass, bone density, and facial hair. As men age, testosterone levels tend to decline naturally, leading to various symptoms such as fatigue, reduced libido, and loss of muscle mass. Testosterone replacement therapy involves the administration of exogenous testosterone through methods such as injections, patches, gels, or pellets implanted under the skin. The goal is to restore testosterone levels to a normal range and alleviate associated symptoms.

The testosterone replacement therapy market growth is attributed rise in prevalence of hypogonadism and the rising incidence of chronic diseases such as obesity, diabetes, and metabolic syndrome, which are associated with an increased risk of low testosterone levels. The prevalence of hypogonadism has witnessed a notable rise in recent years, emerging as a significant driver for the growth of testosterone replacement therapy market. Hypogonadism, characterized by the insufficient production of testosterone in the testes, affects a considerable portion of the male population, particularly as they age. For instance, according to 2021 report by National Library of Medicine, it was estimated that the prevalence of hypogonadism in middle-aged and older men varies between 2.1% and 38.7%. Testosterone replacement therapy has become a primary choice for healthcare professionals in addressing the hormonal imbalances associated with hypogonadism. Thus, a rise in prevalence of hypogonadism is expected to drive the growth of the market.

In addition, rise in incidence of chronic diseases such as obesity and diabetes which causes low testosterone is expected to drive the market growth. Chronic diseases, including diabetes, obesity, and cardiovascular ailments, have become increasingly prevalent worldwide, contributing to a surge in individuals experiencing hormonal imbalances, particularly low testosterone levels. Scientific studies have established a direct correlation between chronic illnesses and reduced testosterone production, creating a substantial patient pool seeking effective therapeutic interventions to treat low testosterone levels. According to 2023 report by National Library of Medicine, it was reported that male obesity is linked to hormonal disturbances leading to impaired gonadal functions, both hormonal and reproductive. Male obesity-related hypogonadism has been reported in up to 45% of patients with moderate to severe obesity. Thus, rise in incidence of chronic diseases, such as obesity and diabetes, is expected to drive the growth of the testosterone replacement therapy market. However, side effects associated with the chemical peels and photo therapy restrain the growth of the market. According to the 2023 report by American College of Cardiology Foundation, it was reported that the incidence of pulmonary embolism, nonfatal arrhythmia, atrial fibrillation, and acute injury was higher in subjects who received testosterone replacement therapy.

The testosterone replacement therapy market is segmented on the basis of product type, active ingredient, end user, and region. By product type, the market is classified into injectables, topical, and others. Other product types include oral, implant, and intranasal formulations. By active ingredient, the market is divided into testosterone cypionate, testosterone, testosterone enanthate, testosterone undecanoate, others. By end user, it is segregated into hospitals, and clinics. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA).

Major key players that operate in the testosterone replacement therapy market are AbbVie Inc, Besins Healthcare SA, Acerus Pharmaceuticals Corporation, Amneal Pharmaceuticals Inc., Acrux Ltd., Endo International Plc, Biote Medical, LLC, Pfizer Inc., Insud Pharma S.L, and Marius Pharmaceuticals. Key players have adopted acquisition as a key developmental strategy to improve the product portfolio of the testosterone replacement therapy market

Key Benefits For Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the testosterone replacement therapy market analysis from 2022 to 2032 to identify the prevailing testosterone replacement therapy market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the testosterone replacement therapy market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global testosterone replacement therapy market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

• Injectables
• Topical
• Others

By Active ingredients

• Testosterone Undecanoate
• Others
• Testosterone Cypionate
• Testosterone
• Testosterone Enanthate

By End User

• Hospital
• Clinics

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Colombia
  • Argentina
  • Rest of Latin America
• Middle East and Africa
  • Gcc
  • South Africa
  • North Africa
  • Rest Of Mea

Key Market Players:

• AbbVie Inc.
• Besins Healthcare SA
• Acerus Pharmaceuticals Corporation
• Amneal Pharmaceuticals Inc.
• Acrux Ltd.
• Endo International plc.
• Biote Medical LLC
• Insud Pharma S.L
• Marius Pharmaceuticals
• Pfizer Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
• 3.4. Market dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: TESTOSTERONE REPLACEMENT THERAPY MARKET, BY PRODUCT TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Injectables
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Topical
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Others
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country

CHAPTER 5: TESTOSTERONE REPLACEMENT THERAPY MARKET, BY ACTIVE INGREDIENTS

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Testosterone Cypionate
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Testosterone
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Testosterone Enanthate
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Testosterone Undecanoate
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country
• 5.6. Others
  • 5.6.1. Key market trends, growth factors and opportunities
  • 5.6.2. Market size and forecast, by region
  • 5.6.3. Market share analysis by country

CHAPTER 6: TESTOSTERONE REPLACEMENT THERAPY MARKET, BY END USER

• 6.1. Overview
  • 6.1.1. Market size and forecast
• 6.2. Hospital
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by region
  • 6.2.3. Market share analysis by country
• 6.3. Clinics
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by region
  • 6.3.3. Market share analysis by country

CHAPTER 7: TESTOSTERONE REPLACEMENT THERAPY MARKET, BY REGION

• 7.1. Overview
  • 7.1.1. Market size and forecast By Region
• 7.2. North America
  • 7.2.1. Key market trends, growth factors and opportunities
  • 7.2.2. Market size and forecast, by Product Type
  • 7.2.3. Market size and forecast, by Active ingredients
  • 7.2.4. Market size and forecast, by End User
  • 7.2.5. Market size and forecast, by country
    • 7.2.5.1. U.S.
    • 7.2.5.1.1. Market size and forecast, by Product Type
    • 7.2.5.1.2. Market size and forecast, by Active ingredients
    • 7.2.5.1.3. Market size and forecast, by End User
    • 7.2.5.2. Canada
    • 7.2.5.2.1. Market size and forecast, by Product Type
    • 7.2.5.2.2. Market size and forecast, by Active ingredients
    • 7.2.5.2.3. Market size and forecast, by End User
    • 7.2.5.3. Mexico
    • 7.2.5.3.1. Market size and forecast, by Product Type
    • 7.2.5.3.2. Market size and forecast, by Active ingredients
    • 7.2.5.3.3. Market size and forecast, by End User
• 7.3. Europe
  • 7.3.1. Key market trends, growth factors and opportunities
  • 7.3.2. Market size and forecast, by Product Type
  • 7.3.3. Market size and forecast, by Active ingredients
  • 7.3.4. Market size and forecast, by End User
  • 7.3.5. Market size and forecast, by country
    • 7.3.5.1. Germany
    • 7.3.5.1.1. Market size and forecast, by Product Type
    • 7.3.5.1.2. Market size and forecast, by Active ingredients
    • 7.3.5.1.3. Market size and forecast, by End User
    • 7.3.5.2. France
    • 7.3.5.2.1. Market size and forecast, by Product Type
    • 7.3.5.2.2. Market size and forecast, by Active ingredients
    • 7.3.5.2.3. Market size and forecast, by End User
    • 7.3.5.3. UK
    • 7.3.5.3.1. Market size and forecast, by Product Type
    • 7.3.5.3.2. Market size and forecast, by Active ingredients
    • 7.3.5.3.3. Market size and forecast, by End User
    • 7.3.5.4. Italy
    • 7.3.5.4.1. Market size and forecast, by Product Type
    • 7.3.5.4.2. Market size and forecast, by Active ingredients
    • 7.3.5.4.3. Market size and forecast, by End User
    • 7.3.5.5. Spain
    • 7.3.5.5.1. Market size and forecast, by Product Type
    • 7.3.5.5.2. Market size and forecast, by Active ingredients
    • 7.3.5.5.3. Market size and forecast, by End User
    • 7.3.5.6. Rest of Europe
    • 7.3.5.6.1. Market size and forecast, by Product Type
    • 7.3.5.6.2. Market size and forecast, by Active ingredients
    • 7.3.5.6.3. Market size and forecast, by End User
• 7.4. Asia-Pacific
  • 7.4.1. Key market trends, growth factors and opportunities
  • 7.4.2. Market size and forecast, by Product Type
  • 7.4.3. Market size and forecast, by Active ingredients
  • 7.4.4. Market size and forecast, by End User
  • 7.4.5. Market size and forecast, by country
    • 7.4.5.1. Japan
    • 7.4.5.1.1. Market size and forecast, by Product Type
    • 7.4.5.1.2. Market size and forecast, by Active ingredients
    • 7.4.5.1.3. Market size and forecast, by End User
    • 7.4.5.2. China
    • 7.4.5.2.1. Market size and forecast, by Product Type
    • 7.4.5.2.2. Market size and forecast, by Active ingredients
    • 7.4.5.2.3. Market size and forecast, by End User
    • 7.4.5.3. India
    • 7.4.5.3.1. Market size and forecast, by Product Type
    • 7.4.5.3.2. Market size and forecast, by Active ingredients
    • 7.4.5.3.3. Market size and forecast, by End User
    • 7.4.5.4. Australia
    • 7.4.5.4.1. Market size and forecast, by Product Type
    • 7.4.5.4.2. Market size and forecast, by Active ingredients
    • 7.4.5.4.3. Market size and forecast, by End User
    • 7.4.5.5. South Korea
    • 7.4.5.5.1. Market size and forecast, by Product Type
    • 7.4.5.5.2. Market size and forecast, by Active ingredients
    • 7.4.5.5.3. Market size and forecast, by End User
    • 7.4.5.6. Rest of Asia-Pacific
    • 7.4.5.6.1. Market size and forecast, by Product Type
    • 7.4.5.6.2. Market size and forecast, by Active ingredients
    • 7.4.5.6.3. Market size and forecast, by End User
• 7.5. Latin America
  • 7.5.1. Key market trends, growth factors and opportunities
  • 7.5.2. Market size and forecast, by Product Type
  • 7.5.3. Market size and forecast, by Active ingredients
  • 7.5.4. Market size and forecast, by End User
  • 7.5.5. Market size and forecast, by country
    • 7.5.5.1. Brazil
    • 7.5.5.1.1. Market size and forecast, by Product Type
    • 7.5.5.1.2. Market size and forecast, by Active ingredients
    • 7.5.5.1.3. Market size and forecast, by End User
    • 7.5.5.2. Colombia
    • 7.5.5.2.1. Market size and forecast, by Product Type
    • 7.5.5.2.2. Market size and forecast, by Active ingredients
    • 7.5.5.2.3. Market size and forecast, by End User
    • 7.5.5.3. Argentina
    • 7.5.5.3.1. Market size and forecast, by Product Type
    • 7.5.5.3.2. Market size and forecast, by Active ingredients
    • 7.5.5.3.3. Market size and forecast, by End User
    • 7.5.5.4. Rest of Latin America
    • 7.5.5.4.1. Market size and forecast, by Product Type
    • 7.5.5.4.2. Market size and forecast, by Active ingredients
    • 7.5.5.4.3. Market size and forecast, by End User
• 7.6. Middle East and Africa
  • 7.6.1. Key market trends, growth factors and opportunities
  • 7.6.2. Market size and forecast, by Product Type
  • 7.6.3. Market size and forecast, by Active ingredients
  • 7.6.4. Market size and forecast, by End User
  • 7.6.5. Market size and forecast, by country
    • 7.6.5.1. Gcc
    • 7.6.5.1.1. Market size and forecast, by Product Type
    • 7.6.5.1.2. Market size and forecast, by Active ingredients
    • 7.6.5.1.3. Market size and forecast, by End User
    • 7.6.5.2. South Africa
    • 7.6.5.2.1. Market size and forecast, by Product Type
    • 7.6.5.2.2. Market size and forecast, by Active ingredients
    • 7.6.5.2.3. Market size and forecast, by End User
    • 7.6.5.3. North Africa
    • 7.6.5.3.1. Market size and forecast, by Product Type
    • 7.6.5.3.2. Market size and forecast, by Active ingredients
    • 7.6.5.3.3. Market size and forecast, by End User
    • 7.6.5.4. Rest Of Mea
    • 7.6.5.4.1. Market size and forecast, by Product Type
    • 7.6.5.4.2. Market size and forecast, by Active ingredients
    • 7.6.5.4.3. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

• 8.1. Introduction
• 8.2. Top winning strategies
• 8.3. Product mapping of top 10 player
• 8.4. Competitive dashboard
• 8.5. Competitive heatmap
• 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

• 9.1. AbbVie Inc.
  • 9.1.1. Company overview
  • 9.1.2. Key executives
  • 9.1.3. Company snapshot
  • 9.1.4. Operating business segments
  • 9.1.5. Product portfolio
  • 9.1.6. Business performance
  • 9.1.7. Key strategic moves and developments
• 9.2. Besins Healthcare SA
  • 9.2.1. Company overview
  • 9.2.2. Key executives
  • 9.2.3. Company snapshot
  • 9.2.4. Operating business segments
  • 9.2.5. Product portfolio
  • 9.2.6. Business performance
  • 9.2.7. Key strategic moves and developments
• 9.3. Acerus Pharmaceuticals Corporation
  • 9.3.1. Company overview
  • 9.3.2. Key executives
  • 9.3.3. Company snapshot
  • 9.3.4. Operating business segments
  • 9.3.5. Product portfolio
  • 9.3.6. Business performance
  • 9.3.7. Key strategic moves and developments
• 9.4. Amneal Pharmaceuticals Inc.
  • 9.4.1. Company overview
  • 9.4.2. Key executives
  • 9.4.3. Company snapshot
  • 9.4.4. Operating business segments
  • 9.4.5. Product portfolio
  • 9.4.6. Business performance
  • 9.4.7. Key strategic moves and developments
• 9.5. Acrux Ltd.
  • 9.5.1. Company overview
  • 9.5.2. Key executives
  • 9.5.3. Company snapshot
  • 9.5.4. Operating business segments
  • 9.5.5. Product portfolio
  • 9.5.6. Business performance
  • 9.5.7. Key strategic moves and developments
• 9.6. Endo International plc.
  • 9.6.1. Company overview
  • 9.6.2. Key executives
  • 9.6.3. Company snapshot
  • 9.6.4. Operating business segments
  • 9.6.5. Product portfolio
  • 9.6.6. Business performance
  • 9.6.7. Key strategic moves and developments
• 9.7. Biote Medical LLC
  • 9.7.1. Company overview
  • 9.7.2. Key executives
  • 9.7.3. Company snapshot
  • 9.7.4. Operating business segments
  • 9.7.5. Product portfolio
  • 9.7.6. Business performance
  • 9.7.7. Key strategic moves and developments
• 9.8. Insud Pharma S.L
  • 9.8.1. Company overview
  • 9.8.2. Key executives
  • 9.8.3. Company snapshot
  • 9.8.4. Operating business segments
  • 9.8.5. Product portfolio
  • 9.8.6. Business performance
  • 9.8.7. Key strategic moves and developments
• 9.9. Marius Pharmaceuticals
  • 9.9.1. Company overview
  • 9.9.2. Key executives
  • 9.9.3. Company snapshot
  • 9.9.4. Operating business segments
  • 9.9.5. Product portfolio
  • 9.9.6. Business performance
  • 9.9.7. Key strategic moves and developments
• 9.10. Pfizer Inc.
  • 9.10.1. Company overview
  • 9.10.2. Key executives
  • 9.10.3. Company snapshot
  • 9.10.4. Operating business segments
  • 9.10.5. Product portfolio
  • 9.10.6. Business performance
  • 9.10.7. Key strategic moves and developments